PMID- 32129203
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210111
IS  - 1319-2442 (Print)
IS  - 1319-2442 (Linking)
VI  - 31
IP  - 1
DP  - 2020 Jan-Feb
TI  - Ribavirin as a beneficial treatment option for hepatitis C virusassociated 
      glomerular disease.
PG  - 109-117
LID - 10.4103/1319-2442.279930 [doi]
AB  - The management of hepatitis C virus (HCV)-induced glomerular disease remains 
      unsatisfactory despite novel advances in antiviral and immunosuppressive therapy. 
      Recent evidence highlighted the role of ribavirin, a drug provided with 
      immunomodulatory properties, in the treatment of glomerular diseases associated 
      with chronic HCV. We administered low-dose ribavirin (200 mg/day or 200 mg twice 
      a week or 200 mg thrice weekly) in a prospective fashion to a group of patients 
      with HCV-associated glomerular disease (n = 7). Ribavirin monotherapy was given 
      in most (n = 6) patients and was accompanied by erythropoietin therapy in all. 
      The primary endpoint was reduction of 24-h proteinuria after treatment ended; the 
      secondary end-points were decrease in serum creatinine and amelioration of 
      urinary abnormalities. We collected data on on-treatment adverse events (AEs), 
      serious AEs, and laboratory abnormalities. Many patients (n = 6) had inactive HCV 
      infection as they had shown HCV RNA clearance from serum after antiviral therapy 
      with direct-acting antivirals. Some patients (n = 4) had membranoproliferative 
      glomerulo- nephritis, the diagnosis being confirmed by kidney histology in three 
      cases; others (n = 2) received diagnosis of diabetic glomerulosclerosis, 
      confirmed in one by kidney biopsy. We observed consistent reduction of 24-h 
      proteinuria in two individuals after ribavirin therapy; another patient reported 
      disappearance of microscopic hematuria. We found severe AE (hemolytic anemia) in 
      three patients which required discontinuation of ribavirin treatment in two 
      patients, one required hospitalization. Other AEs were cutaneous rash (n = 1), 
      dyspepsia (n = 1), and fatigue (n = 1). Low-dose ribavirin was able to give 
      consistent reduction of 24-h proteinuria in two patients; tolerance to ribavirin 
      was unsatisfactory. We need further studies aimed to expand our knowledge on 
      ribavirin therapy of HCV-associated glomerular disease. The low incidence of the 
      disease hampers the conduction of clinical trials on this aim.
FAU - Fabrizi, Fabrizio
AU  - Fabrizi F
AD  - Division of Nephrology, Maggiore Hospital and IRCCS Foundation, Milano, Italy.
FAU - Cresseri, Donata
AU  - Cresseri D
AD  - Division of Nephrology, Maggiore Hospital and IRCCS Foundation, Milano, Italy.
FAU - Moroni, Gabriella
AU  - Moroni G
AD  - Division of Nephrology, Maggiore Hospital and IRCCS Foundation, Milano, Italy.
FAU - Passerini, Patrizia
AU  - Passerini P
AD  - Division of Nephrology, Maggiore Hospital and IRCCS Foundation, Milano, Italy.
FAU - Pallotti, Francesco
AU  - Pallotti F
AD  - Division of Pathology, Maggiore Hospital and IRCCS Foundation, Milano, Italy.
FAU - Donato, Francesca Maria
AU  - Donato FM
AD  - Division of Gastroenterology, Maggiore Hospital and IRCCS Foundation, Milano, 
      Italy.
FAU - Lampertico, Pietro
AU  - Lampertico P
AD  - Division of Gastroenterology, Maggiore Hospital and IRCCS Foundation; Deparment 
      of Medicine, University School of Medicine, Milano, Italy.
FAU - Messa, Piergiorgio
AU  - Messa P
AD  - Division of Nephrology, Maggiore Hospital and IRCCS Foundation; Deparment of 
      Medicine, University School of Medicine, Milano, Italy.
LA  - eng
PT  - Journal Article
PL  - Saudi Arabia
TA  - Saudi J Kidney Dis Transpl
JT  - Saudi journal of kidney diseases and transplantation : an official publication of 
      the Saudi Center for Organ Transplantation, Saudi Arabia
JID - 9436968
RN  - 0 (Antiviral Agents)
RN  - 49717AWG6K (Ribavirin)
SB  - IM
MH  - Aged
MH  - Antiviral Agents/adverse effects/*therapeutic use
MH  - Female
MH  - Hepatitis C, Chronic/complications/*drug therapy
MH  - Humans
MH  - Kidney Diseases/*drug therapy/virology
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Ribavirin/adverse effects/*therapeutic use
MH  - Treatment Outcome
EDAT- 2020/03/05 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/03/05 06:00
PHST- 2020/03/05 06:00 [entrez]
PHST- 2020/03/05 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - SaudiJKidneyDisTranspl_2020_31_1_109_279930 [pii]
AID - 10.4103/1319-2442.279930 [doi]
PST - ppublish
SO  - Saudi J Kidney Dis Transpl. 2020 Jan-Feb;31(1):109-117. doi: 
      10.4103/1319-2442.279930.